Global Dry Eye Syndrome Drugs Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Dry Eye Syndrome Drugs market size will reach US$ 7862 million by 2031.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment. In this report, we mainly study the drugs and eye drops for dry eye.
The Dry Eye Syndrome market is driven by the rising prevalence of dry eye conditions globally, fueled by aging populations, increased screen time, and lifestyle-related factors. The widespread use of digital devices has significantly contributed to eye strain and reduced blink rates, leading to a surge in dry eye cases, especially among younger demographics. Additionally, growing awareness of ocular health and improved diagnosis through advanced diagnostic tools have increased patient identification and treatment rates. The introduction of innovative therapies, including anti-inflammatory eye drops, tear-stimulating drugs, and device-based treatments, is also expanding the market landscape.
Despite growing demand, the Dry Eye Syndrome market faces several challenges, including underdiagnosis, variable symptoms, and limited long-term treatment efficacy. Many patients remain undiagnosed due to the overlap of symptoms with other ocular conditions and the subjective nature of the disease. Current treatments often offer only temporary relief rather than a cure, leading to poor adherence and patient dissatisfaction. Moreover, the development of new therapies is hindered by the complex pathophysiology of the condition, which involves both aqueous and evaporative components. Addressing these challenges requires improved diagnostic criteria, personalized treatment approaches, and increased investment in research and clinical trials.
LPI (LP Information)' newest research report, the “Dry Eye Syndrome Drugs Industry Forecast” looks at past sales and reviews total world Dry Eye Syndrome Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Dry Eye Syndrome Drugs sales for 2025 through 2031. With Dry Eye Syndrome Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dry Eye Syndrome Drugs industry.
This Insight Report provides a comprehensive analysis of the global Dry Eye Syndrome Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dry Eye Syndrome Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dry Eye Syndrome Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dry Eye Syndrome Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dry Eye Syndrome Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Syndrome Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Artificial Tears
Anti-inflammatory Drugs
Other
Segmentation by Application:
Hospitals
Clinics
Homecare
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)
Please note: The report will take approximately 2 business days to prepare and deliver.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment. In this report, we mainly study the drugs and eye drops for dry eye.
The Dry Eye Syndrome market is driven by the rising prevalence of dry eye conditions globally, fueled by aging populations, increased screen time, and lifestyle-related factors. The widespread use of digital devices has significantly contributed to eye strain and reduced blink rates, leading to a surge in dry eye cases, especially among younger demographics. Additionally, growing awareness of ocular health and improved diagnosis through advanced diagnostic tools have increased patient identification and treatment rates. The introduction of innovative therapies, including anti-inflammatory eye drops, tear-stimulating drugs, and device-based treatments, is also expanding the market landscape.
Despite growing demand, the Dry Eye Syndrome market faces several challenges, including underdiagnosis, variable symptoms, and limited long-term treatment efficacy. Many patients remain undiagnosed due to the overlap of symptoms with other ocular conditions and the subjective nature of the disease. Current treatments often offer only temporary relief rather than a cure, leading to poor adherence and patient dissatisfaction. Moreover, the development of new therapies is hindered by the complex pathophysiology of the condition, which involves both aqueous and evaporative components. Addressing these challenges requires improved diagnostic criteria, personalized treatment approaches, and increased investment in research and clinical trials.
LPI (LP Information)' newest research report, the “Dry Eye Syndrome Drugs Industry Forecast” looks at past sales and reviews total world Dry Eye Syndrome Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Dry Eye Syndrome Drugs sales for 2025 through 2031. With Dry Eye Syndrome Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dry Eye Syndrome Drugs industry.
This Insight Report provides a comprehensive analysis of the global Dry Eye Syndrome Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dry Eye Syndrome Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dry Eye Syndrome Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dry Eye Syndrome Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dry Eye Syndrome Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Syndrome Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Artificial Tears
Anti-inflammatory Drugs
Other
Segmentation by Application:
Hospitals
Clinics
Homecare
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
124 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Dry Eye Syndrome Drugs Market Size by Player
- 4 Dry Eye Syndrome Drugs by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Dry Eye Syndrome Drugs Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
